Single-center study reports on the effects of oropharyngeal cancer treatment at 3, 6, and 12 months after chemoradiotherapy or radiotherapy alone, and with and without a feeding tube.
This study assessed causes of early mortality stratified by HPV status in oropharynx cancer.
In a randomized phase 3 trial, researchers sought to determine if cetuximab-based chemoradiotherapy could be a less-toxic alternative to cisplatin-based chemoradiotherapy in patients with HPV-positive oropharyngeal cancer.
Incidence was greatest among white men aged 60 to 64 years.
HPV gene signature was associated with outcomes in patients with HPV-related oropharyngeal cancers and could become a prognostic biomarker.
Oropharyngeal cancers have become the most common HPV-associated malignancies in the US, where the rate of vaccination against HPV lags compared with other countries.
Researchers are evaluating whether DPX-E7 vaccination is safe and will improve outcomes among patients with HPV-positive head and neck, cervical, or anal cancer.
Researchers are evaluating whether ADXS 11-001 vaccination prior to transoral surgery will improve outcomes for patients with HPV-positive oropharyngeal cancer.
Findings suggest that TORS is a promising strategy for improving swallowing function in patients with OPSCC, without compromising disease-free survival.
The ICON-S developed a TNM classification specific to human papillomavirus (HPV)-related oropharyngeal cancer.
